北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Interferon-alpha: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
作者: Mo, Xiao-Dong1,2; Zhang, Xiao-Hui1,2; Xu, Lan-Ping1,2; Wang, Yu1,2; Yan, Chen-Hua1,2; Chen, Huan1,2; Chen, Yu-Hong1,2; Han, Wei1,2; Wang, Feng-Rong1,2; Wang, Jing-Zhi1,2; Liu, Kai-Yan1,2; Huang, Xiao-Jun1,2,3,4
关键词: Donor lymphocyte infusion ; Hematopoietic stem cell transplantation ; IFN-alpha ; Minimal residual disease ; Preemptive
刊名: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
发表日期: 2015-11-01
DOI: 10.1016/j.bbmt.2015.06.014
卷: 21, 期:11, 页:1939-1947
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Hematology ; Immunology ; Transplantation
研究领域[WOS]: Hematology ; Immunology ; Transplantation
关键词[WOS]: VERSUS-HOST-DISEASE ; ACUTE MYELOID-LEUKEMIA ; DONOR LYMPHOCYTE INFUSION ; BONE-MARROW-TRANSPLANTATION ; HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; IN-VITRO ; MYELODYSPLASTIC SYNDROME ; COMORBIDITY INDEX ; WORKING PARTY ; FREE SURVIVAL
英文摘要:

In this prospective clinical study, the safety and efficacy of preemptive interferon-alpha (IFN-alpha) treatment were investigated and compared with preemptive donor lymphocyte infusion (DLI) in patients who were minimal residual disease (MRD)-positive after allogeneic hematopoietic stem cell transplantation (HSCT). Patients undergoing allogeneic HSCT were eligible if they had acute leukemia or myelodysplastic syndrome and were MRD-positive after HSCT. Patients who were able to receive DLI were assigned to a preemptive DLI group (n = 45); patients who could not or did not agree to receive DLI after HSCT received preemptive IFN-alpha. A total of 22 patients received preemptive IFN-alpha; the median treatment duration was 35 days (range, 4 to 180 days). Seven patients relapsed, and 1 patient died from severe pneumonia. The 1-year cumulative incidence of chronic graft-versus-host disease (cGVHD) after intervention was 90.9% for the IFN-alpha group and 62.9% for the DLI group (P < .001). MRD status after preemptive intervention was comparable in the 2 groups, and the 1-year cumulative incidence of relapse after intervention was 27.3% for the IFN-alpha group and 35.6% for the DLI group (P = .514). The 1-year cumulative incidence of nonrelapse mortality after intervention was 4.5% for the IFN-alpha, group and 4.4% for the DLI group (P = .985). The 1-year probability of disease-free survival after intervention was 68.2% for the IFN-alpha group and 60.0% for the DLI group (P = .517). In multivariate analysis, early-onset MRD, persistent MRD after intervention, and absence of cGVHD after intervention were significantly associated with poorer clinical outcomes. Thus, preemptive IFN-alpha may be a potential alternative for MRD-positive patients who cannot receive preemptive DLI after HSCT. (C) 2015 American Society for Blood and Marrow Transplantation.

语种: 英语
所属项目编号: 81230013 ; 2013AA020401 ; 30971292 ; 81400145
项目资助者: Key Program of the National Natural Science Foundation of China ; National High Technology Research and Development Program of China (Program 863) ; National Natural Science Foundation of China
WOS记录号: WOS:000363357200013
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/51952
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China
2.Peking Univ, Inst Hematol, Beijing 100044, Peoples R China
3.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
4.Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China

Recommended Citation:
Mo, Xiao-Dong,Zhang, Xiao-Hui,Xu, Lan-Ping,et al. Interferon-alpha: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION,2015,21(11):1939-1947.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Mo, Xiao-Dong]'s Articles
[Zhang, Xiao-Hui]'s Articles
[Xu, Lan-Ping]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Mo, Xiao-Dong]‘s Articles
[Zhang, Xiao-Hui]‘s Articles
[Xu, Lan-Ping]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace